112 related articles for article (PubMed ID: 38265973)
1. Potential prognosis and immunotherapy predictor TFAP2A in pan-cancer.
Niu C; Wen H; Wang S; Shu G; Wang M; Yi H; Guo K; Pan Q; Yin G
Aging (Albany NY); 2024 Jan; 16(2):1021-1048. PubMed ID: 38265973
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
4. Long Non-Coding RNA TFAP2A-AS1 Inhibits Cell Proliferation and Invasion in Breast Cancer via miR-933/SMAD2.
Zhou B; Guo H; Tang J
Med Sci Monit; 2019 Feb; 25():1242-1253. PubMed ID: 30768589
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment.
Lv J; Jiang Z; Yuan J; Zhuang M; Guan X; Liu H; Yin Y; Ma Y; Liu Z; Wang H; Wang X
Front Immunol; 2023; 14():1093716. PubMed ID: 37006239
[TBL] [Abstract][Full Text] [Related]
6. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
7. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
8. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
9. TFAP2A activates HMGA1 to promote glycolysis and lung adenocarcinoma progression.
Zhao J; Lan G
Pathol Res Pract; 2023 Sep; 249():154759. PubMed ID: 37586214
[TBL] [Abstract][Full Text] [Related]
10. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
11. A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint.
Lu H; Liang J; He X; Ye H; Ruan C; Shao H; Zhang R; Li Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298135
[TBL] [Abstract][Full Text] [Related]
12. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
13. HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated TFAP2A/DDR1 axis.
Lian B; Yan S; Li J; Bai Z; Li J
Mol Med; 2023 Aug; 29(1):103. PubMed ID: 37528369
[TBL] [Abstract][Full Text] [Related]
14. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
15. TFAP2A promotes cervical cancer via a positive feedback pathway with PD‑L1.
Yang J; Gao Y; Yao S; Wan S; Cai H
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37083077
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
17. Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltrates: A pan-cancer analysis.
Xu J; Ma H; Shan B
PLoS One; 2022; 17(10):e0273163. PubMed ID: 36194583
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
19. Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.
Zhu C; Wang S; Du Y; Dai Y; Huai Q; Li X; Du Y; Dai H; Yuan W; Yin S; Wang H
BMC Gastroenterol; 2022 Oct; 22(1):437. PubMed ID: 36253721
[TBL] [Abstract][Full Text] [Related]
20. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
